Curevac N.V. Stock
Price
Target price
€2.99
€2.99
1.080%
0.032
1.080%
€504.00
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Financial data and news for Curevac
sharewise wants to provide you with the best news and tools for Curevac, so we directly link to the best financial data sources.
Financials
News
EQS-News: CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
EQS-News: CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
EQS-News: CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
EQS-News: CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
EQS-News: CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
EQS-News: CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
EQS-News: CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update
EQS-News: CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update
EQS-News: CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma
EQS-News: CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma
EQS-News: CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board
EQS-News: CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board
EQS-News: CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech
EQS-News: CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech
EQS-News: CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities
EQS-News: CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities
EQS-News: GSK and CureVac to Restructure Collaboration into New Licensing Agreement
EQS-News: GSK and CureVac to Restructure Collaboration into New Licensing Agreement
EQS-News: CureVac Announces Voting Results of General Meeting
EQS-News: CureVac Announces Voting Results of General Meeting
EQS-News: CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK
EQS-News: CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK
EQS-News: CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update
EQS-News: CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update
EQS-News: CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
EQS-News: CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
EQS-News: CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
EQS-News: CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
EQS-News: CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
EQS-News: CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
EQS-News: CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
EQS-News: CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
EQS-News: CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
EQS-News: CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
EQS-News: CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
EQS-News: CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK